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REGULATORY AGENCY ACTION
and falls within the scope of the practice
of optometry. However, on May 1,
Board staff responded to these inquiries,
stating that the "use of collagen implants
by an optometrist would not be within
the current scope of optometric prac-
tice."
Board Relocates Office. Effective
June 10, the Board moved its office to a
new location at 400 R Street, Suite 3130,
Sacramento, CA 95814.
LEGISLATION:
SB 664 (Calderon), as introduced
March 5, would prohibit optometrists,
among others, from charging, billing, or
otherwise soliciting payment from any
patient, client, customer, or third-party
payor for any clinical laboratory test or
service if the test or service was not
actually rendered by that person or under
his/her direct supervision, except as
specified. This bill is pending in the Sen-
ate Business and Professions Commit-
tee.
AB 1479 (Burton). The Robert W.
Crown California Children's Services
Act requires the Department of Health
Services (DHS) to establish and admin-
ister a program of services for physically
defective or handicapped persons under
the age of 21 years; the Act requires the
DHS Director to establish those condi-
tions coming within the definition of
"handicapped child." As amended May
29, this bill would require any condition
established by the Director which is
treatable by an ophthalmologist to be
deemed treatable by an optometrist if the
condition is within the scope of practice
of optometry. This bill is pending in the
Assembly Ways and Means Committee.
The following is a status update on
bills reported. in detail in CRLR Vol. 11,
No. 2 (Spring 1991) at page 96:
AB 1124 (Frizzelle), as introduced
March 5, would, among other things,
establish the right, duty, responsibility,
and obligation of a person engaged in
the practice of optometry to exercise
professional judgment in the perfor-
mance of his/her duties, including but
not limited to scheduling, diagnosis,
treatment within the scope of practice of
optometry, and referral of patients. This
bill is pending in the Assembly Health
Committee.
AB 1358 (Floyd), as introduced
March 7, would specify that a registered
optometrist who performs any act con-
stituting the practice of optometry while
employed by another optometrist, a
physician, or any entity authorized by
the laws of this state to employ an
optometrist to perform acts constituting
the practice of optometry is bound by
and subject to the optometry statutes and
regulations. This bill would also specify
that the Board may suspend or revoke
the certificate of registration of, or other-
wise discipline, an optometrist who is
employed as described above for any of
the causes specified in the optometry
statutes or regulations. This bill is pend-
ing in the Assembly Health Committee.
SB 613 (Calderon). Existing law
requires a registered optometrist who
temporarily practices optometry outside
or away from his/her regular place of
practice to deliver to each patient there
fitted or supplied with glasses a specified
receipt. As amended April 15, this bill
would instead require a registered
optometrist to furnish to each patient
there fitted or supplied with prescription
spectacle lenses a specified receipt. This
bill passed the Senate on May 2 and is
pending in the Assembly Health Com-
mittee.
AB 1046 (Tucker), as introduced
March 4, would add optometrists to the
list of individuals required to report any
evidence of abuse of an elderly or depen-
dent person. This bill was passed by the
Assembly on May 30 and is pending in
the Senate Judiciary Committee.
LITIGATION:
April 8 was the Federal Trade Com-
mission's (FTC) deadline for seeking
U.S. Supreme Court review of the D.C.
Circuit's decision in California State
Board of Optometry v. Federal Trade
Commission, 910 F.2d 976 (D.C. Cir.
1990). The FTC failed to file a petition
for certiorari; thus, the Board has pre-
vailed in its challenge to the FTC's juris-
diction to adopt rules prohibiting state
boards of optometry from engaging in
anticompetitive conduct. (See CRLR
Vol. 11, No. 2 (Spring 1991) p. 96; Vol.
11, No. 1 (Winter 1991) p. 81; and Vol.
10, No. 4 (Fall 1990) pp. 97-98 for back-
ground information on this case.)
RECENT MEETINGS:
At its May 23 meeting, the Board
reviewed a draft of its Consumer Educa-
tion Pamphlet, which is expected to be
released in late 1991. The pamphlet con-
tains information about the Board;
defines the differences between an
optometrist, an ophthalmologist, and an
optician; describes common eye and
refractive conditions; discusses environ-
mental considerations relevant to eye
safety; describes the contents of an ade-
quate eye examination; provides infor-
mation about contact lenses; informs
consumers about steps to take if they are
dissatisfied with the services received;
and discusses the confidentiality of a
patient's records and the patient's right
to obtain copies of his/her records.
FUTURE MEETINGS:
August 22-23 in San Francisco.
November 18-19 in Los Angeles.
BOARD OF PHARMACY
Executive Officer: Patricia Harris
(916) 445-5014
Pursuant to Business and Professions
Code section 4000 et seq., the Board of
Pharmacy grants licenses and permits to
pharmacists, pharmacies, drug manufac-
turers, wholesalers and sellers of hypo-
dermic needles. It regulates all sales of
dangerous drugs, controlled substances
and poisons. The Board is authorized to
adopt regulations, which are codified in
Division 17, Title 16 of the California
Code of Regulations (CCR). To enforce
its regulations, the Board employs full-
time inspectors who investigate accusa-
tions and complaints received by the
Board. Investigations may be conducted
openly or covertly as the situation
demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized
by law to suspend or revoke licenses or
permits for a variety of reasons, includ-
ing professional misconduct and any acts
substantially related to the practice of
pharmacy.
The Board consists of ten members,
three of whom are public. The remaining
members are pharmacists, five of whom
must be active practitioners. All are
appointed for four-year terms.
MAJOR PROJECTS:
Pharmacy Shortage. On April 23, the
Board submitted written testimony to the
Office of Statewide Health Planning and
Development regarding the shortage of
pharmacists in California. The Office
had solicited testimony in conjunction
with two statewide hearings it conducted
during April and May, the results of
which will be compiled in a report to the
legislature with findings and recommen-
dations relative to the need for allied
health professionals in California.
In its testimony, the Board noted that
there is a general consensus among inter-
ested parties that the pharmacy shortage
is due in part to outside influences on the
profession (such as insurance compa-
nies) which are dictating practice deci-
sions; practicing pharmacists discourag-
ing students from entering into the
profession; job dissatisfaction due to
stress and long hours; difficulty with the
California examination; and significant
changes in the pharmacist population.
According to the Board, there are a
number of possible responses to the
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shortage, including the legalized use of
pharmacy technicians (see infra LEGIS-
LATION); addressing quality of life
issues (better salaries and working con-
ditions); partial licensure reciprocity
between states; having the profession
take a firm, unified position on issues
regarding contracts and reimbursements;
and focusing recruiting efforts at an ear-
ly point in a student's education.
The Board concluded its testimony
by noting that resolution of the pharma-
cist shortage will probably be based on
several factors, but stated that one of the
key elements will be the use of pharma-
cy technicians for all those functions that
pharmacists do not need to perform, but
which require pharmacist supervision.
Investigation of Revenue Enhance-
ment Programs Between Physician and
Home IV Providers. The Board's sub-
committee investigating concerns over
fee arrangements between physicians
and home infusion companies has turned
over the information it has compiled
from pharmacists and other sources to
the Attorney General's office; the AG's
office hopes to prepare a recommenda-
tion for the Board to consider at its July
meeting. (See CRLR Vol. 11, No. 2
(Spring 1991) p. 97; Vol. 11, No. 1 (Win-
ter 1991) p. 82; and Vol. 10, No. 4 (Fall
1990) pp. 98-99 for background infor-
mation.)
In a related issue, AB 819 (Speier)
would amend Business and Professions
Code section 650 to provide that, subject
to specified exceptions, it is unlawful for
licensed health professionals to refer a
person to any laboratory, pharmacy, clin-
ic, or health care facility which is owned
in whole or in part by the licensee or in
which the licensee has a proprietary
interest. (See infra LEGISLATION.)
Attorney General Opinion No: 91-
305. At its March 20 meeting, the Board
discussed a request by Assemblymem-
ber Tricia Hunter for an Attorney Gener-
al's opinion concerning the following
questions:
-Do the laws affecting pharmacies
dispensing drugs in California also apply
to out-of-state mail order pharmacies
filling prescriptions for people living or
at least using an address in California?
-Would state regulation of out-of-
state mail order pharmacies be forbidden
by federal regulation of interstate com-
merce?
-Would a drug listed on California's
negative drug formulary, making it ille-
gal to dispense in California, also be ille-
gal for out-of-state pharmacies to dis-
pense via mail in California?
At the meeting, Deputy Attorney
General William Marcus opined that the
Board is authorized to regulate mail
order pharmacies, and may have the
authority to require prescriptions to com-
ply with certain provisions of the Health
and Safety Code. Mr. Marcus added that
a formal Attorney General's Opinion on
the matter is forthcoming.
In a related issue, the Board recently
considered the Mail Order Pharmacy
Survey Report prepared by the U.S.
Food and Drug Administration's (FDA)
Center for Drug Evaluation and
Research, and concluded that, at this
time, there is no indication of abuse in
the mail order pharmacy industry (see
infra).
Nonresidential Pharmacy Complaint
Information. At its May 29 meeting, the
Board reviewed a report it submitted to
the legislature on March 29 regarding
complaints involving nonresidential
pharmacies. The report was prepared
pursuant to SB 2213 (Craven) (Chapter
1424, Statutes of 1988), which requires
the Board to maintain a record of all
nonresidential pharmacy complaint
referrals involving serious bodily or psy-
chological injury to a resident of this
state and any action taken against a
licensee as a result of a referral, and to
report its findings to the legislature. (See
CRLR Vol. 8, No. 4 (Fall 1988) p. 70 for
background information.)
The report noted that during the
reporting period of October 1, 1988
through March 22, 1991, the Board
received twelve complaints concerning
alleged nonresidential pharmacy viola-
tions. Of the twelve complaints, nine
were referred for review and appropriate
action to the regulatory/licensing agency
in the state in which the pharmacy was
located; the remaining three complaints
were investigated by the Board but not
referred to another state agency. The
major category of complaint was pre-
scription error, including cases where the
container was properly labeled but con-
tained the wrong medication. Two com-
plaints involved patient harm; those
complaints are presently under investi-
gation by other state agencies.
According to the report, it is the
Board's policy to investigate and track
all complaints concerning nonresidential
pharmacies, and such investigations are
handled no differently than an investiga-
tion of a California pharmacy.
Nuclear Pharmacy. At its March 20
meeting, the Board continued its discus-
sion regarding the potential confusion
between the Nuclear Regulatory Com-
mission's (NRC). jurisdiction over pos-
session and handling of all radioactive
materials and the guidelines for medical
licensees (including radiopharmacists)
established by the Radiologic Health
Branch (RHB) of the state Department
of Health Services (DHS). (See CRLR
Vol. 11, No. 2 (Spring 1991) p. 9 7 for
background information.)
At the meeting, former Board mem-
ber Glenn Yokoyama reported that he
and Board Supervising Inspector Ken
Sain attended an NRC Agreement State
Meeting regarding NRC's proposal to
adopt a Quality Assurance Rule. Califor-
nia is an agreement state, which means
that NRC delegated its authority to regu-
late nuclear medicine to RHB. However,
it appears to some parties that NRC's
proposed rule would preempt that dele-
gation and negatively impact the practice
of nuclear medicine and pharmacy in
California. Because of this, the Board
opposes NRC's proposed rule.
Mr. Yokoyama reported that it
appears that the NRC will adopt the rule
despite the comments made by the
agreement states. The Board unanimous-
ly voted to contact NRC officials and
reaffirm its opposition to the Quality
Assurance Rule.
Licensure of Drug Wholesalers. On
April 12, the Board published notice of
its intent to amend section 1780, Title 16
of the CCR, regarding minimum stan-
dards for drug wholesalers. In 1987, the
federal Prescription Drug Marketing Act
directed the FDA to adopt national stan-
dards for the state licensure of drug
wholesalers. In September 1990, the
FDA adopted these standards and pub-
lished them in the Federal Register The
standards require all states to license
drug wholesalers by September 15,
1992, in compliance with FDA's mini-
mum requirements.
According to the Board, California
must add several provisions to its exist-
ing requirements in order to achieve
compliance with the federal standards.
These new provisions, which would be
added to section 1780, deal with security
systems to protect drugs stored or han-
dled by a wholesaler; inspection require-
ments for incoming or outgoing ship-
ments; procedures for handling returned,
damaged, or outdated drugs; and
requirements concerning written proce-
dures, policies, and staffing.
Under the proposed changes, whole-
salers would be required to have an
alarm system, exterior lighting, and a
security system protecting against inter-
nal thefts. Incoming shipments must be
examined for container damage. Outgo-
ing shipments must be inspected to
ensure product identity and integrity.
Drugs which are returned, damaged, or
outdated, or whose outer or inner con-
tainer seals have been broken must be
physically separated from other drugs.
Wholesalers must establish and maintain
written policies and procedures for the
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receipt, security, storage, inventory, and
distribution of drugs. Wholesalers would
also be required to maintain records in
accordance with federal provisions for at
least three years, including the names of
officers, directors, and managers, as well
as their duties and qualifications.
After a May 29 public hearing on the
proposed revisions, the Board adopted
the amendments subject to minor modi-
fications. The Board was expected to
release the modified text for a 15-day
public comment period during late June
or early July.
Compounding for Office Use. Also
on May 29, the Board held a regulatory
hearing concerning its proposal to adopt
new sections 1716.1 and 1716.2, regard-
ing the definition of the "reasonable
quantity of compounded medication"
which a pharmacist may furnish to a pre-
scriber for office use under Business and
Professions Code section 4046(c)(1).
(See CRLR Vol. 11, No. 2 (Spring 1991)
p. 98; Vol. 11, No. 1 (Winter 1991)p. 83;
and Vol. 10, Nos. 2 & 3 (Spring/Summer
1990) p. 115 for background information
on the Attorney General's Opinion
which prompted these regulatory
changes.)
Proposed new section 1716.1 would
clarify the definition of the terms "rea-
sonable quantity," "compounded," and
"prescriber office use," as referenced in
section 4046(c)(1). The term "reason-
able quantity" would be defined as a
quantity not to exceed that which is suf-
ficient for a prescriber's office use for
180 days; that which is reasonable based
upon its intended use, the nature of the
prescriber's practice, and the stability of
the compounded medication; and that
which the pharmacy can safely com-
pound and supply. The term "prescriber
office use" would be defined as applica-
tion or administration in the office or
distribution to patients of not more than
a 72-hour supply.
Proposed new section 1716.2 would
specify the minimum types of records
that pharmacies must keep when they
furnish compounded medications to pre-
scribers in quantities larger than required
for the prescriber's immediate office use
or when a pharmacy compounds medi-
cation for future furnishing. Those
records would include the date of prepa-
ration, lot number, expiration date (in no
event to exceed six months), signature or
initial of the compounding pharmacist,
and a description of the product, includ-
ing its formula, manufacturer of raw
materials, quantity, package size, and
number of units prepared.
Following the May 29 hearing, the
Board decided that technical refinements
to the language may be necessary; the
Board was scheduled to review a modi-
fied version of the text at its July 31
meeting in San Diego.
Regulatory Update. The following is
a status update on regulatory changes
considered and approved by the Board in
recent months (see CRLR Vol. 11, No. 2
(Spring 1991) p. 98; Vol. 11, No. 1 (Win-
ter 1991) p. 83; and Vol. 10, No. 4 (Fall
1990) pp. 99-100 for background infor-
mation on these changes):
-Continuing Education Advertising.
The Board's proposed revision to section
1732.3(d), pertaining to continuing edu-
cation advertising, was recently
approved by the Director of the Depart-
ment of Consumer Affairs (DCA) and
was scheduled for submission to the
Office of Administrative Law (OAL) for
review in mid-June.
-Processing Times for Applications
and Registrations. Proposed new section
1706.1 specifies the time periods within
which the Board will process applica-
tions pursuant to the Permit Reform Act
of 1981, Government Code section
15374 et seq. The DCA Director
approved the new section in May; the
Board expected to submit the rulemak-
ing package to OAL for review in mid-
June.
LEGISLATION:
SB 664 (Calderon), as introduced
March 5, would prohibit pharmacists,
among others, from charging, billing, or
otherwise soliciting payment from any
patient, client, customer, or third-party
payor for any clinical laboratory test or
service if the test or service was not actu-
ally rendered by that person or under
his/her direct supervision, except as
specified. This bill is pending in the Sen-
ate Business and Professions Commit-
tee.
The following is a status update on
bills reported in detail in CRLR Vol. 11,
No. 2 (Spring 1991) at pages 98-99:
AB 1226 (Hunter), as introduced
March 6, would change the standard to
be applied by the Director of the Depart-
ment of Health Services (DHS) in estab-
lishing a formulary of generic drug types
and drug products, to require him/her to
identify those generic drug types and
drug products which, if substituted by a
pharmacist for a drug product described
by the prescriber by its trade or brand
name, may pose a threat to the health
and safety of patients. This bill would
also require the Director to consider all
information submitted by any person
who requests that the Director make any
inclusion, addition, or deletion of a
generic drug type or drug product to the
formulary. This bill is pending in the
Assembly Health Committee.
AB 1253 (Baker). Existing law per-
mits the Board to waive specified licen-
sure requirements for pharmacies, hospi-
tal pharmacies, and medical device
retailers, as defined, if, in the opinion of
the Board, a-high standard of patient
safety can be provided. As amended
April 29, this bill would permit the
Board to waive any requirement of licen-
sure for pharmacies, hospital phar-
macies, and medical device retailers if
those conditions are met. This bill would
also provide that existing regulations do
not prohibit the storage of medical
devices in secure central or ward supply
areas of specified establishments. This
bill is pending in the Assembly Ways
and Means Committee.
AB 1371 (Wright). Existing law con-
tains a variety of provisions regulating
medical device retailers, with which
each retailer must comply on or before
July 1, 1991. As amended May 23, this
bill would extend the date for compli-
ance until July 1, 1992 for home health
agencies and hospices licensed under
specified provisions. During the one-
year period of exemption, this bill would
require the Board, licensed home health
agencies, and licensed hospices to work
together to develop language for legisla-
tion regarding the handling of dangerous
devices by home health agencies and
hospices that proposes safeguards neces-
sary to protect the public health and that
is least restrictive on the functioning of
home health agencies and hospices. This
bill passed the Assembly on May 29 and
is pending in the Senate Business and
Professions Committee.
AB 1893 (Lancaster), as amended
May 24, would revise the applicability
of pharmacy laws with respect to certain
medical supplies; retitle the Impaired
Pharmacist Program, scheduled for
repeal on January 1, 1992, as the "Phar-
macist Recovery Program" and continue
its provisions indefinitely; and extend
indefinitely provisions of existing law
which authorize the Board, until January
1, 1992, to deny, revoke, or suspend a
nonresident pharmacy registration for
conduct which causes serious bodily or
psychological injury to a resident of this
state, subject to specified conditions.
This bill is pending in the Assembly
Ways and Means Committee.
SB 1033 (Marks), as introduced
March 8, would permit pharmacists to
manufacture, measure, fit to the patient,
sell, and repair medical devices without re-
gard to whether they bear a specified le-
gend relating to a federal prohibition
against dispensing without a prescription.
This bill is pending in the Senate Busi-
ness and Professions Committee.
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AB 855 (Hunter), as introduced
February 27, would provide that
notwithstanding any other provision of
law, no pharmacist in filling a prescrip-
tion for a drug product described by its
trade or brand name shall select another
drug product pursuant to these provi-
sions if the U.S. Secretary of Health and
Human Services or the U.S. Commis-
sioner of Food and Drugs has proposed
to withdraw the generic drug from the
market, and has issued a notice of oppor-
tunity for a hearing because the drug
lacks substantial evidence of effective-
ness for all labeled indications and for
which the Secretary or Commissioner
has made no determination that there is
compelling justification for its medical
need. This bill passed the Assembly on
May 30 and is pending in the Senate
Business and Professions Committee.
AB 1244 (Polanco), as amended May
6, would permit a pharmacy technician,
as defined, to perform packaging,
manipulative, repetitive, or other nondis-
cretionary tasks while assisting, and
while under the direct supervision of, a
registered pharmacist. This bill is pend-
ing in the Assembly Health Committee.
SB 917 (Kopp), as amended May 2,
would require certain health care service
plans that propose to offer a pharmacy
benefit or change its relationship with
pharmacy providers to give written or
published notice to pharmacy service
providers of the plan's proposal, and
give those providers an opportunity to
submit a bid to participate in the plan's
panel of providers on the terms pro-
posed. This bill is pending in the Senate
Committee on Insurance, Claims and
Corporations.
AB 1675 (Margolin), as introduced
March 8, would require the Board to
designate a statewide drug information
center for the purpose of offering direct
telephone assistance or referral to health
care providers for any person desiring
information relating to prescription
drugs. The bill would require the Board
to provide on license renewal forms an
opportunity to make voluntary contribu-
tions to the statewide drug information
center. This bill passed the Assembly on
May 30 and is pending in the Senate
Business and Professions Committee.
AB 819 (Speier). Existing law pro-
vides that it is not unlawful for pre-
scribed licensed health professionals to
refer a person to a laboratory, pharmacy,
clinic, or health care facility solely
because the licensee has a proprietary
interest or coownership in the facility.
As introduced February 27, this bill
would instead provide that, subject to
specified exceptions, it is unlawful for
these licensed health professionals to
refer a person to any laboratory, pharma-
cy, clinic, or health care facility which is
owned in whole or in part by the licensee
or in which the licensee has a proprietary
interest; the bill would also provide that
disclosure of the ownership or propri-
etary interest would not exempt the
licensee from the prohibition. This bill is
pending in the Assembly Health Com-
mittee.
SB 594 (Roberti), as amended May 8,
would require the State Department of
Alcohol and Drug Programs and the
Department of Aging to jointly adminis-
ter a statewide roundtable to develop a
consistent, long-term medication educa-
tion program model for elderly con-
sumers. This bill is pending on the Sen-
ate floor.
RECENT MEETINGS:
At the Board's March 20 meeting,
Executive Officer Patricia Harris
announced that the Board's budget is in
good shape and that there should be ade-
quate funding to sustain all Board opera-
tions through the end of the fiscal year.
Also in March, the Board announced
that Board member and actress Cindy
Williams recently filmed a 30-second
public service announcement (PSA) on
the Board's new mandatory oral consul-
tation regulation. (See CRLR Vol. 11,
No. 2 (Spring 1991) p. 98; Vol. 10, Nos.
2 & 3 (Spring/Summer 1990) p. 115; and
Vol. 10, No. I (Winter 1990) p. 90 for
background information.) The PSA
stresses to consumers the importance of
asking their pharmacist when they have
questions regarding their medications.
The PSA will be distributed to television
stations throughout the state.
At the Board's May 29 meeting, staff
reported that it is processing a budget
change proposal (BCP) seeking budget
authorization for the 1992-93 fiscal year
to install a toll-free telephone line for
consumers to use to contact the Board;
the Board is seeking three staff positions
to handle these calls, and would redirect
certain portions of its enforcement work-
load to these staff positions. This BCP
was to be submitted to the Department of
Consumer Affairs for review in June.
Also at the May meeting, the Board
announced that it is relocating its offices
to 400 R Street, Sacramento, California
95814; the move was expected to take
place in early June.
FUTURE MEETINGS:
October 16-17 in Los Angeles.
January 22-23 in Sacramento.
March 18-19 in San Diego.
BOARD OF REGISTRATION FOR
PROFESSIONAL ENGINEERS
AND LAND SURVEYORS
Executive Officer: Darlene Stroup
(916) 920-7466
The Board of Registration for Profes-
sional Engineers and Land Surveyors
(PELS) regulates the practice of engi-
neering and land surveying through its
administration of the Professional Engi-
neers Act, sections 6700 through 6799 of
the Business and Professions Code, and
the Professional Land Surveyors' Act,
sections 8700 through 8805 of the Busi-
ness and Professions Code. The Board's
regulations are found in Division 5, Title
16 of the California Code of Regulations
(CCR).
The basic functions of the Board are
to conduct examinations, issue certifi-
cates, registrations, and/or licenses, and
appropriately channel complaints against
registrants/licensees. The Board is addi-
tionally empowered to suspend or
revoke registrations/licenses. The Board
considers the proposed decisions of
administrative law judges who hear
appeals of applicants who are denied a
registration/license, and those who have
had their registration/license suspended
or revoked for violations.
The Board consists of thirteen mem-
bers: seven public members, one
licensed land surveyor, four registered
Practice Act engineers and one Title Act
engineer. Eleven of the members are
appointed by the Governor for four-year
terms which expire on a staggered basis.
One public member is appointed by the
Speaker of the Assembly and one by the
Senate President pro Tempore.
The Board has established four stand-
ing committees and appoints other spe-
cial committees as needed. The four
standing committees are Administration,
Enforcement, Examination/Qualifica-
tions, and Legislation. The committees
function in an advisory capacity unless
specifically authorized to make binding
decisions by the Board.
Professional engineers are registered
through the three Practice Act categories
of civil, electrical, and mechanical engi-
neering under section 6730 of the Busi-
ness and Professions Code. The Title Act
categories of agricultural, chemical, con-
trol system, corrosion, fire protection,
industrial, manufacturing, metallurgical,
nuclear, petroleum, quality, safety, and
traffic engineering are registered under
section 6732 of the Business and Profes-
sions Code.
Structural engineering and geotechni-
cal engineering are authorities linked to
the civil Practice Act and require an
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